It was announced today that after observing significant benefits in overall survival (OS) and radiographic progression free survival (PFS) ,the two co-primary endpoints of the the Xtandi pre-chemotherapy trial, the Independent Data Monitoring Committee (IDMC) for The Phase 3 PREVAIL trial of enzalutamide in metastatic prostate cancer recommends that "the study be stopped and patients [...]
Step therapy (ST) has again reared its most ugly head in our prostate cancer world, to the detriment of us, prostate cancer survivors and only to the benefit of private insurance payers. So, what is this “creeping crud,” Step Therapy (aka as Fail First Therapy)? Simply, ST is when insurance companies decide, without sound medical [...]
I want to share a post I made today on the advanced prostate cancer online support group ). It was in response to an ongoing thread with a spouse (caregiver) who was fired by her husband's doctor by having his nurse call them. She was guilty of asking questions, relevant and important ones, but the [...]
All of the Americans who receive their insurance benefits from Medicare need to become aware that the Medicare Open Enrollment Period begins today, October 15. What is the Medicare open enrollment period?During this open enrollment period you can make new choices and pick plans that work best for you depending upon your doctors and [...]
At the 2013 European Cancer Congress in Amsterdam Dr. Howard Scher from Sloan Kettering Hospital reported that a panel of biomarkers could identify men with metastatic, castration-resistant prostate cancer (mCRPC) who were responding well or less well to treatment with Zytiga + prednisone (abiraterone + prednisone). Dr. Scher provided data in his presentation to support [...]